Steatosis degree (measured by means of ultrasound scanning using a 4-point validated scale [86]) was significantly reduced in the treatment group (p < 0.001), and complete steatosis remission was achieved in 21.4% of patients with a 92.86% overall reduction; accordingly, a significant reduction of hepatic necrosis enzymes was reported (ALT from 71 to 39 U/L, AST from 47 to 29 U/L; p < 0.001) [76]. The gene discussed is GPT; the disease is steatosis.